146 related articles for article (PubMed ID: 31072097)
21. Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA.
Rowlands V; Rutkowski AJ; Meuser E; Carr TH; Harrington EA; Barrett JC
Sci Rep; 2019 Sep; 9(1):12620. PubMed ID: 31477768
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.
Cho MS; Park CH; Lee S; Park HS
PLoS One; 2020; 15(3):e0230622. PubMed ID: 32196518
[TBL] [Abstract][Full Text] [Related]
23. A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens.
Alcaide M; Cheung M; Bushell K; Arthur SE; Wong HL; Karasinska J; Renouf D; Schaeffer DF; McNamara S; Tertre MCD; Batist G; Kennecke HF; Karsan A; Morin RD
J Mol Diagn; 2019 Mar; 21(2):214-227. PubMed ID: 30472330
[TBL] [Abstract][Full Text] [Related]
24. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.
Cohen JD; Javed AA; Thoburn C; Wong F; Tie J; Gibbs P; Schmidt CM; Yip-Schneider MT; Allen PJ; Schattner M; Brand RE; Singhi AD; Petersen GM; Hong SM; Kim SC; Falconi M; Doglioni C; Weiss MJ; Ahuja N; He J; Makary MA; Maitra A; Hanash SM; Dal Molin M; Wang Y; Li L; Ptak J; Dobbyn L; Schaefer J; Silliman N; Popoli M; Goggins MG; Hruban RH; Wolfgang CL; Klein AP; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Lennon AM
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10202-10207. PubMed ID: 28874546
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
[TBL] [Abstract][Full Text] [Related]
26. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
[TBL] [Abstract][Full Text] [Related]
27. Selective capture of plasma cell-free tumor DNA on magnetic beads: a sensitive and versatile tool for liquid biopsy.
Kerachian MA; Azghandi M; Javadmanesh A; Ghaffarzadegan K; Mozaffari-Jovin S
Cell Oncol (Dordr); 2020 Oct; 43(5):949-956. PubMed ID: 32495293
[TBL] [Abstract][Full Text] [Related]
28. Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR.
Decraene C; Silveira AB; Bidard FC; Vallée A; Michel M; Melaabi S; Vincent-Salomon A; Saliou A; Houy A; Milder M; Lantz O; Ychou M; Denis MG; Pierga JY; Stern MH; Proudhon C
Clin Chem; 2018 Feb; 64(2):317-328. PubMed ID: 29122835
[TBL] [Abstract][Full Text] [Related]
29. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
30. Detection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies.
Valpione S; Campana L
Methods Enzymol; 2019; 629():1-15. PubMed ID: 31727235
[TBL] [Abstract][Full Text] [Related]
31. Multiplex Preamplification of Serum DNA to Facilitate Reliable Detection of Extremely Rare Cancer Mutations in Circulating DNA by Digital PCR.
Jackson JB; Choi DS; Luketich JD; Pennathur A; Ståhlberg A; Godfrey TE
J Mol Diagn; 2016 Mar; 18(2):235-43. PubMed ID: 26752305
[TBL] [Abstract][Full Text] [Related]
32. Efficient and accurate KRAS genotyping using digital PCR combined with melting curve analysis for ctDNA from pancreatic cancer patients.
Tanaka J; Nakagawa T; Harada K; Morizane C; Tanaka H; Shiba S; Ohba A; Hijioka S; Takai E; Yachida S; Kamura Y; Ishida T; Yokoi T; Uematsu C
Sci Rep; 2023 Feb; 13(1):3039. PubMed ID: 36810451
[TBL] [Abstract][Full Text] [Related]
33. Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer.
Vanova B; Kalman M; Jasek K; Kasubova I; Burjanivova T; Farkasova A; Kruzliak P; Busselberg D; Plank L; Lasabova Z
Clin Exp Med; 2019 May; 19(2):219-224. PubMed ID: 30661213
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
Strijker M; Soer EC; de Pastena M; Creemers A; Balduzzi A; Beagan JJ; Busch OR; van Delden OM; Halfwerk H; van Hooft JE; van Lienden KP; Marchegiani G; Meijer SL; van Noesel CJ; Reinten RJ; Roos E; Schokker S; Verheij J; van de Vijver MJ; Waasdorp C; Wilmink JW; Ylstra B; Besselink MG; Bijlsma MF; Dijk F; van Laarhoven HW
Int J Cancer; 2020 Mar; 146(5):1445-1456. PubMed ID: 31340061
[TBL] [Abstract][Full Text] [Related]
35. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue.
Ako S; Nouso K; Kinugasa H; Dohi C; Matushita H; Mizukawa S; Muro S; Akimoto Y; Uchida D; Tomoda T; Matsumoto K; Horiguchi S; Tsutsumi K; Kato H; Okada H
Pancreatology; 2017; 17(2):285-290. PubMed ID: 28139399
[TBL] [Abstract][Full Text] [Related]
36. Circulating Tumor DNA Is an Accurate Diagnostic Tool and Strong Prognostic Marker in Pancreatic Cancer.
Sellahewa R; Moghaddam SM; Lundy J; Jenkins BJ; Croagh D
Pancreas; 2023 Mar; 52(3):e188-e195. PubMed ID: 37751379
[TBL] [Abstract][Full Text] [Related]
37. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer.
Lin M; Alnaggar M; Liang S; Chen J; Xu K; Dong S; Du D; Niu L
Cell Physiol Biochem; 2018; 47(4):1556-1564. PubMed ID: 29940591
[TBL] [Abstract][Full Text] [Related]
38. Fe-Au Nanoparticle-Coupling for Ultrasensitive Detections of Circulating Tumor DNA.
Hu P; Zhang S; Wu T; Ni D; Fan W; Zhu Y; Qian R; Shi J
Adv Mater; 2018 Aug; 30(31):e1801690. PubMed ID: 29931715
[TBL] [Abstract][Full Text] [Related]
39. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
40. Multiplex Digital PCR Assay to Detect Multiple KRAS and GNAS Mutations Associated with Pancreatic Carcinogenesis from Minimal Specimen Amounts.
Maeda C; Ono Y; Hayashi A; Takahashi K; Taniue K; Kakisaka R; Mori M; Ishii T; Sato H; Okada T; Kawabata H; Goto T; Tamamura N; Omori Y; Takahashi K; Katanuma A; Karasaki H; Liss AS; Mizukami Y
J Mol Diagn; 2023 Jun; 25(6):367-377. PubMed ID: 36965665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
